Faculty

Stacy D. D'Andre, M.D.

Clinical Studies

Complementary Options For Symptom Management In Cancer (COSMIC): Assessing Benefits And Harms Of Cannabis And Cannabinoid Use Among A Cohort Of Cancer Patients Treated In Community Oncology Clinics (COSMIC) Rochester, Minn., Mankato, Minn., La Crosse, Wis., Eau Claire, Wis., Albert Lea, Minn.
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Pilot study of a wearable EEG headband as a meditation device for breast cancer survivors Rochester, Minn.
The purpose of this study is to evaluate the frequency of use of meditation (a stress management technique) among breast cancer survivors.
Reishi Mushroom Extract for fatigue and/or arthralgias in patients with breast cancer on aromatase inhibitors: a randomized phase II MNCCTN trial (MC221002) Rochester, Minn., Mankato, Minn., Albert Lea, Minn.
The purpose of this study is to evaluate the effect of Reishi mushroom extracts on aromatase-inhibitor toxicities, specifically fatigue, and arthralgias, compared to placebo. Other aims include examining the side effects of Reishi mushroom extracts and its impact on quality of life and mood, as compared to placebo.

A Pilot Study Of Mindfulness-Based Stress Reduction (MBSR) In Patients With Cancer Experiencing Stress Who Live In Underserved And Rural Regions Of Minnesota Rochester, Minn.
The purpose of this study is to determine the completion rate of an on demand, virtual stress reduction program (MBSR) in patients with cancer that are experiencing stress or anxiety.
Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-induced Peripheral Neuropathy: A Randomized Placebo-controlled Pilot Trial (MC211003) Rochester, Minn., Mankato, Minn., Albert Lea, Minn.
The primary purpose of this study is to evaluate whether topical CBD improves chemotherapy-induced peripheral neuropathy (CIPN), compared to placebo, and to evaluate side effects from topical CBD cream use, compared to placebo.
Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial Rochester, Minn., Eau Claire, Wis.
The purpose of this study the efectiveness of PEA (N-palmitoylethanolamide) at two different doses relative to placebo responses, as a treatment for chemotherapy-induced neuropathy (CIPN). Also, to assess the safety of PEA at the two study doses, and to evaluate changes in patient-reported symptoms and quality of life from baseline to the end of 8 weeks.